Search

Your search keyword '"Carret, Anne-Sophie"' showing total 301 results
Start Over Author "Carret, Anne-Sophie"
301 results on '"Carret, Anne-Sophie"'

1. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Author

Milowsky, Matthew, ODonnell, Peter, Hoimes, Christopher, Petrylak, Daniel, Flaig, Thomas, Moon, Helen, Friedlander, Terence, Mar, Nataliya, McKay, Rana, Srinivas, Sandy, Gravis, Gwenaelle, Ramamurthy, Chethan, Bupathi, Manojkumar, Bracarda, Sergio, Wright, Phoebe, Hepp, Zsolt, Carret, Anne-Sophie, Yu, Yao, Dillon, Ryan, Kataria, Ritesh, Beaumont, Jennifer, Purnajo, Intan, and Rosenberg, Jonathan

Subjects
Humans, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Cisplatin, Pain, Patient Reported Outcome Measures, Quality of Life, Sleep Initiation and Maintenance Disorders
Abstract

PURPOSE: Locally advanced/metastatic urothelial cancer (la/mUC) affects patients quality of life (QOL) and functioning. We describe the impact of first-line (1L) enfortumab vedotin (EV) alone or with pembrolizumab (P) on QOL/functioning/symptoms in patients with la/mUC who were cisplatin-ineligible from EV-103 Cohort K. METHODS: In this phase Ib/II trial, patients were randomly assigned 1:1 to EV + P or EV monotherapy (mono). Exploratory patient-reported outcomes (PROs) were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core Questionnaire (EORTC QLQ-C30) and Brief Pain Inventory Short Form (BPI-SF) at baseline, once per week for cycles 1-3, and then in every cycle through the end of treatment. Changes in scores from baseline to week 24, reported as least squares mean (standard error), were assessed by mixed models for repeated measures. There were no formal statistical comparisons between treatment arms. RESULTS: Of 149 patients treated, 65 (EV + P) and 63 (EV mono) comprised the PRO analysis set. For EV + P, EORTC QLQ-C30 QOL was maintained through week 24 with improvements in emotional functioning, pain, and insomnia. Clinically meaningful improvements were seen in EORTC QLQ-C30 pain after EV + P at weeks 12 (-14.41 [3.14]) and 24 (-14.99 [3.56]) and BPI-SF worst pain at week 24 (-2.07 [0.37]). For EV mono, EORTC QLQ-C30 QOL remained stable with clinically meaningful improvements in EORTC QLQ-C30 pain (-12.55 [4.27]), insomnia (-14.46 [4.69]), and constipation (-10.09 [4.35]) at week 24. There were small-to-moderate improvements in BPI-SF worst pain at week 24. CONCLUSION: EV + P in patients with la/mUC who were cisplatin-ineligible was associated with preservation or improvement of QOL/functioning/symptoms. Improvement in pain was seen in both PRO instruments and treatment arms. These data complement clinical outcomes of 1L EV + P.

Published
2024

2. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.

Author

Hoimes, Christopher, Flaig, Thomas, Milowsky, Matthew, Bilen, Mehmet, Gupta, Shilpa, Srinivas, Sandy, Merchan, Jaime, McKay, Rana, Petrylak, Daniel, Sasse, Carolyn, Moreno, Blanca, Yu, Yao, Carret, Anne-Sophie, Rosenberg, Jonathan, and Friedlander, Terence

Subjects
enfortumab vedotin, lay summary, pembrolizumab, plain language summary, urothelial cancer, Humans, Urologic Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Abstract

WHAT IS THIS SUMMARY ABOUT?: This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or metastatic urothelial cancer (la/mUC), a cancer that occurs most commonly in the bladder. WHAT WERE THE RESULTS?: In the 45 patients studied, around 16% did have serious side effects, but most side effects were manageable. Twenty-four percent of patients, however, stopped the study treatment because of their side effects. Within about 2 months of starting treatment, most patients (73%) tumors were smaller and stayed smaller, on average, for more than 2 years. WHAT DO THE RESULTS MEAN?: The combination of enfortumab vedotin plus pembrolizumab is a new treatment option for patients with locally advanced or metastatic urothelial cancer when they cannot receive the typical treatment, cisplatin. Advanced or metastatic urothelial cancer is a type of cancer where the cancer has already spread outside of the bladder or urinary tract.

Published
2024

3. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

Author

ODonnell, Peter, Milowsky, Matthew, Petrylak, Daniel, Hoimes, Christopher, Flaig, Thomas, McKay, Rana, Bilen, Mehmet, Srinivas, Sandy, Burgess, Earle, Ramamurthy, Chethan, George, Saby, Geynisman, Daniel, Bracarda, Sergio, Borchiellini, Delphine, Geoffrois, Lionnel, Maroto Rey, Jose, Ferrario, Christiano, Carret, Anne-Sophie, Yu, Yao, Guseva, Maria, Homet Moreno, Blanca, Rosenberg, Jonathan, Moon, Helen, Friedlander, Terence, and Mar, Nataliya

Subjects
Humans, Cisplatin, Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell
Abstract

PURPOSE: Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies. Enfortumab vedotin (EV) and pembrolizumab (Pembro) individually have shown a survival benefit in urothelial cancer in second-line + la/mUC settings. Here, we present data from the pivotal trial of EV plus Pembro (EV + Pembro) in the 1L setting. PATIENTS AND METHODS: In Cohort K of the EV-103 phase Ib/II study, cisplatin-ineligible patients with previously untreated la/mUC were randomly assigned 1:1 to receive EV as monotherapy or in combination with Pembro. The primary end point was confirmed objective response rate (cORR) per blinded independent central review. Secondary end points included duration of response (DOR) and safety. There were no formal statistical comparisons between treatment arms. RESULTS: The cORR was 64.5% (95% CI, 52.7 to 75.1) and 45.2% (95% CI, 33.5 to 57.3) for patients treated with EV + Pembro (N = 76) and EV monotherapy (N = 73), respectively. The median DOR was not reached for the combination and was 13.2 months for monotherapy; 65.4% and 56.3% of patients who responded to the combination and monotherapy, respectively, maintained a response at 12 months. The most common grade 3 or higher treatment-related adverse events (TRAEs) in patients treated with the combination were maculopapular rash (17.1%), fatigue (9.2%), and neutropenia (9.2%). EV TRAEs of special interest (any grade) in the combination arm included skin reactions (67.1%) and peripheral neuropathy (60.5%). CONCLUSION: EV + Pembro showed a high cORR with durable responses as 1L treatment in cisplatin-ineligible patients with la/mUC. Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.

Published
2023

4. Quality of Life

Author

Cacciotti, Chantel, Carret, Anne-Sophie, Scheinemann, Katrin, editor, and Bouffet, Eric, editor

Published
2024
Full Text
View/download PDF

5. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.

Author

Hoimes, Christopher, Flaig, Thomas, Milowsky, Matthew, Bilen, Mehmet, Gupta, Shilpa, Srinivas, Sandy, Merchan, Jaime, McKay, Rana, Petrylak, Daniel, Sasse, Carolyn, Moreno, Blanca, Yu, Yao, Carret, Anne-Sophie, Rosenberg, Jonathan, and Friedlander, Terence

Subjects
Humans, Cisplatin, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Neoplasms
Abstract

PURPOSE: Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial, responses are rarely durable, and many patients with la/mUC are ineligible. Each enfortumab vedotin and pembrolizumab have shown a survival benefit versus chemotherapy in UC, are not restricted by cisplatin eligibility, and warrant investigation as a first-line (1L) combination therapy in patients ineligible for cisplatin. METHODS: In this ongoing phase Ib/II, multicenter, open-label study, 1L cisplatin-ineligible patients with la/mUC received enfortumab vedotin 1.25 mg/kg once daily on days 1 and 8 and pembrolizumab 200 mg (day 1) intravenously once daily in 3-week cycles. The primary end point was safety. Key secondary end points included confirmed objective response rate, duration of response (DOR), and overall survival (OS). RESULTS: Forty-five patients received enfortumab vedotin plus pembrolizumab. The most common treatment-related adverse events (TRAEs) were peripheral sensory neuropathy (55.6%), fatigue (51.1%), and alopecia (48.9%). Twenty-nine patients (64.4%) had grade 3 or higher TRAEs; the most common were increased lipase (17.8%), maculopapular rash (11.1%), and fatigue (11.1%). One death (2.2%) was classified as a TRAE. The confirmed objective response rate after a median of nine cycles was 73.3% with a complete response rate of 15.6%. The median DOR and median OS were 25.6 months and 26.1 months, respectively. CONCLUSION: Enfortumab vedotin plus pembrolizumab showed a manageable safety profile. Most patients experienced tumor shrinkage. The median DOR and median OS exceeding 2 years in a cisplatin-ineligible patient population make this a promising combination currently under investigation in a phase III study (ClinicalTrials.gov identifier: NCT04223856).

Published
2023

6. Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.

Author

Sun, Lova, primary, Fayette, Jerome, additional, Salas, Sebastien, additional, Hong, David S., additional, Adkins, Douglas, additional, Dunn, Lara, additional, Ciardiello, Fortunato, additional, Cirauqui, Beatriz, additional, William, William Nassib, additional, Saba, Nabil F., additional, Chung, Christine H., additional, Birnbaum, Ariel E., additional, Zandberg, Dan Paul, additional, Wehr, Allison, additional, Viana Nicacio, Leonardo, additional, Soumaoro, Ibrahima, additional, Carret, Anne-Sophie, additional, and Seiwert, Tanguy Y., additional

Published
2024
Full Text
View/download PDF

7. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome

Author

Panwalkar, Pooja, Clark, Jonathan, Ramaswamy, Vijay, Hawes, Debra, Yang, Fusheng, Dunham, Christopher, Yip, Stephen, Hukin, Juliette, Sun, Yilun, Schipper, Matthew J, Chavez, Lukas, Margol, Ashley, Pekmezci, Melike, Chung, Chan, Banda, Adam, Bayliss, Jill M, Curry, Sarah J, Santi, Mariarita, Rodriguez, Fausto J, Snuderl, Matija, Karajannis, Matthias A, Saratsis, Amanda M, Horbinski, Craig M, Carret, Anne-Sophie, Wilson, Beverly, Johnston, Donna, Lafay-Cousin, Lucie, Zelcer, Shayna, Eisenstat, David, Silva, Marianna, Scheinemann, Katrin, Jabado, Nada, McNeely, P Daniel, Kool, Marcel, Pfister, Stefan M, Taylor, Michael D, Hawkins, Cynthia, Korshunov, Andrey, Judkins, Alexander R, and Venneti, Sriram

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Brain Disorders, Genetics, Brain Cancer, Rare Diseases, Neurosciences, Clinical Research, Pediatric Cancer, Cancer, Clinical Trials and Supportive Activities, Pediatric, Child, Child, Preschool, Disease-Free Survival, Ependymoma, Female, Humans, Infant, Infratentorial Neoplasms, Jumonji Domain-Containing Histone Demethylases, Male, Prognosis, Registries, Survival Rate, Childhood ependymoma, Epigenetics, H3K27me3, Molecular subgrouping, Neurology & Neurosurgery
Abstract

Posterior fossa ependymomas (EPN_PF) in children comprise two morphologically identical, but biologically distinct tumor entities. Group-A (EPN_PFA) tumors have a poor prognosis and require intensive therapy. In contrast, group-B tumors (EPN_PFB) exhibit excellent prognosis and the current consensus opinion recommends future clinical trials to test the possibility of treatment de-escalation in these patients. Therefore, distinguishing these two tumor subtypes is critical. EPN_PFA and EPN_PFB can be distinguished based on DNA methylation signatures, but these assays are not routinely available. We have previously shown that a subset of poorly prognostic childhood EPN_PF exhibits global reduction in H3K27me3. Therefore, we set out to determine whether a simple immunohistochemical assay for H3K27me3 could be used to segregate EPN_PFA from EPN_PFB tumors. We assembled a cohort of 230 childhood ependymomas and H3K27me3 immunohistochemistry was assessed as positive or negative in a blinded manner. H3K27me3 staining results were compared with DNA methylation-based subgroup information available in 112 samples [EPN_PFA (n = 72) and EPN_PFB tumors (n = 40)]. H3K27me3 staining was globally reduced in EPN_PFA tumors and immunohistochemistry showed 99% sensitivity and 100% specificity in segregating EPN_PFA from EPN_PFB tumors. Moreover, H3K27me3 immunostaining was sufficient to delineate patients with worse prognosis in two independent, non-overlapping cohorts (n = 133 and n = 97). In conclusion, immunohistochemical evaluation of H3K27me3 global reduction is an economic, easily available and readily adaptable method for defining high-risk EPN_PFA from low-risk posterior fossa EPN_PFB tumors to inform prognosis and to enable the design of future clinical trials.

Published
2017

8. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors

Author

Torchia, Jonathon, Golbourn, Brian, Feng, Shengrui, Ho, Ching, Sin-Chan, Patrick, Vasiljevic, Alexandre, Norman, Joseph D, Guilhamon, Paul, Garzia, Livia, Agamez, Natalia R, Lu, Mei, Chan, Tiffany S, Picard, Daniel, de Antonellis, Pasqualino, Khuong-Quang, Dong-Anh, Planello, Aline C, Zeller, Constanze, Barsyte-Lovejoy, Dalia, Lafay-Cousin, Lucie, Letourneau, Louis, Bourgey, Mathieu, Yu, Man, Gendoo, Deena MA, Dzamba, Misko, Barszczyk, Mark, Medina, Tiago, Riemenschneider, Alexandra N, Morrissy, A Sorana, Ra, Young-Shin, Ramaswamy, Vijay, Remke, Marc, Dunham, Christopher P, Yip, Stephen, Ng, Ho-keung, Lu, Jian-Qiang, Mehta, Vivek, Albrecht, Steffen, Pimentel, Jose, Chan, Jennifer A, Somers, Gino R, Faria, Claudia C, Roque, Lucia, Fouladi, Maryam, Hoffman, Lindsey M, Moore, Andrew S, Wang, Yin, Choi, Seung Ah, Hansford, Jordan R, Catchpoole, Daniel, Birks, Diane K, Foreman, Nicholas K, Strother, Doug, Klekner, Almos, Bognár, Laszló, Garami, Miklós, Hauser, Péter, Hortobágyi, Tibor, Wilson, Beverly, Hukin, Juliette, Carret, Anne-Sophie, Van Meter, Timothy E, Hwang, Eugene I, Gajjar, Amar, Chiou, Shih-Hwa, Nakamura, Hideo, Toledano, Helen, Fried, Iris, Fults, Daniel, Wataya, Takafumi, Fryer, Chris, Eisenstat, David D, Scheinemann, Katrin, Fleming, Adam J, Johnston, Donna L, Michaud, Jean, Zelcer, Shayna, Hammond, Robert, Afzal, Samina, Ramsay, David A, Sirachainan, Nongnuch, Hongeng, Suradej, Larbcharoensub, Noppadol, Grundy, Richard G, Lulla, Rishi R, Fangusaro, Jason R, Druker, Harriet, Bartels, Ute, Grant, Ronald, Malkin, David, McGlade, C Jane, Nicolaides, Theodore, Tihan, Tarik, Phillips, Joanna, Majewski, Jacek, Montpetit, Alexandre, Bourque, Guillaume, Bader, Gary D, Reddy, Alyssa T, Gillespie, G Yancey, and Warmuth-Metz, Monika

Subjects
Genetics, Human Genome, Rare Diseases, Orphan Drug, Cancer, 2.1 Biological and endogenous factors, Development of treatments and therapeutic interventions, Aetiology, 5.1 Pharmaceuticals, Cell Line, Tumor, Cell Proliferation, Cell Survival, Central Nervous System Neoplasms, Chromatin, DNA Methylation, Dasatinib, Epigenesis, Genetic, Epigenomics, Humans, Mutation, Protein Kinase Inhibitors, Pyrimidines, Receptor, Platelet-Derived Growth Factor beta, Rhabdoid Tumor, SMARCB1 Protein, Teratoma, ATRT, enhancer, epigenomics, genomics, rhabdoid tumors, subgroup-specific therapeutics, Neurosciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

We recently reported that atypical teratoid rhabdoid tumors (ATRTs) comprise at least two transcriptional subtypes with different clinical outcomes; however, the mechanisms underlying therapeutic heterogeneity remained unclear. In this study, we analyzed 191 primary ATRTs and 10 ATRT cell lines to define the genomic and epigenomic landscape of ATRTs and identify subgroup-specific therapeutic targets. We found ATRTs segregated into three epigenetic subgroups with distinct genomic profiles, SMARCB1 genotypes, and chromatin landscape that correlated with differential cellular responses to a panel of signaling and epigenetic inhibitors. Significantly, we discovered that differential methylation of a PDGFRB-associated enhancer confers specific sensitivity of group 2 ATRT cells to dasatinib and nilotinib, and suggest that these are promising therapies for this highly lethal ATRT subtype.

Published
2016

9. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.

Author

Fontebasso, Adam, Papillon-Cavanagh, Simon, Schwartzentruber, Jeremy, Nikbakht, Hamid, Gerges, Noha, Fiset, Pierre-Olivier, Bechet, Denise, Faury, Damien, De Jay, Nicolas, Ramkissoon, Lori, Corcoran, Aoife, Jones, David, Sturm, Dominik, Johann, Pascal, Tomita, Tadanori, Goldman, Stewart, Nagib, Mahmoud, Bendel, Anne, Goumnerova, Liliana, Bowers, Daniel, Leonard, Jeffrey, Rubin, Joshua, Alden, Tord, Browd, Samuel, Geyer, J, Leary, Sarah, Jallo, George, Cohen, Kenneth, Carret, Anne-Sophie, Ellezam, Benjamin, Crevier, Louis, Klekner, Almos, Bognar, Laszlo, Hauser, Peter, Garami, Miklos, Myseros, John, Dong, Zhifeng, Siegel, Peter, Malkin, Hayley, Ligon, Azra, Albrecht, Steffen, Pfister, Stefan, Ligon, Keith, Majewski, Jacek, Jabado, Nada, Kieran, Mark, Prados, Michael, and Gupta, Nalin

Subjects
Activin Receptors, Type I, Animals, Astrocytoma, Base Sequence, Bone Morphogenetic Proteins, Brain Neoplasms, Child, DNA Copy Number Variations, DNA Methylation, Gene Expression Regulation, Neoplastic, Genome, Human, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Molecular Sequence Data, Mutation, Sequence Analysis, DNA, Smad Proteins
Abstract

Pediatric midline high-grade astrocytomas (mHGAs) are incurable with few treatment targets identified. Most tumors harbor mutations encoding p.Lys27Met in histone H3 variants. In 40 treatment-naive mHGAs, 39 analyzed by whole-exome sequencing, we find additional somatic mutations specific to tumor location. Gain-of-function mutations in ACVR1 occur in tumors of the pons in conjunction with histone H3.1 p.Lys27Met substitution, whereas FGFR1 mutations or fusions occur in thalamic tumors associated with histone H3.3 p.Lys27Met substitution. Hyperactivation of the bone morphogenetic protein (BMP)-ACVR1 developmental pathway in mHGAs harboring ACVR1 mutations led to increased levels of phosphorylated SMAD1, SMAD5 and SMAD8 and upregulation of BMP downstream early-response genes in tumor cells. Global DNA methylation profiles were significantly associated with the p.Lys27Met alteration, regardless of the mutant histone H3 variant and irrespective of tumor location, supporting the role of this substitution in driving the epigenetic phenotype. This work considerably expands the number of potential treatment targets and further justifies pretreatment biopsy in pediatric mHGA as a means to orient therapeutic efforts in this disease.

Published
2014

10. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab

Author

Hoimes, Christopher J, primary, Flaig, Thomas W, additional, Milowsky, Matthew I, additional, Friedlander, Terence W, additional, Bilen, Mehmet Asim, additional, Gupta, Shilpa, additional, Srinivas, Sandy, additional, Merchan, Jaime R, additional, McKay, Rana R, additional, Petrylak, Daniel P, additional, Sasse, Carolyn, additional, Moreno, Blanca Homet, additional, Yu, Yao, additional, Carret, Anne-Sophie, additional, and Rosenberg, Jonathan E, additional

Published
2023
Full Text
View/download PDF

11. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Author

O'Donnell, Peter H., primary, Milowsky, Matthew I., additional, Petrylak, Daniel P., additional, Hoimes, Christopher J., additional, Flaig, Thomas W., additional, Mar, Nataliya, additional, Moon, Helen H., additional, Friedlander, Terence W., additional, McKay, Rana R., additional, Bilen, Mehmet A., additional, Srinivas, Sandy, additional, Burgess, Earle F., additional, Ramamurthy, Chethan, additional, George, Saby, additional, Geynisman, Daniel M., additional, Bracarda, Sergio, additional, Borchiellini, Delphine, additional, Geoffrois, Lionnel, additional, Maroto Rey, Jose Pablo, additional, Ferrario, Christiano, additional, Carret, Anne-Sophie, additional, Yu, Yao, additional, Guseva, Maria, additional, Homet Moreno, Blanca, additional, and Rosenberg, Jonathan E., additional

Published
2023
Full Text
View/download PDF

16. Quality of Life

Author

Pépin, Annie-Jade, Carret, Anne-Sophie, Sultan, Serge, Scheinemann, Katrin, editor, and Bouffet, Eric, editor

Published
2015
Full Text
View/download PDF

18. Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.

Author

O'Donnell, Peter H., primary, Rosenberg, Jonathan E., additional, Hoimes, Christopher J., additional, Petrylak, Daniel P., additional, Milowsky, Matthew I., additional, McKay, Rana R., additional, Srinivas, Sandy, additional, Friedlander, Terence W., additional, Ramamurthy, Chethan, additional, Bilen, Mehmet Asim, additional, Burgess, Earle F, additional, Mar, Nataliya, additional, Moon, Helen, additional, Geynisman, Daniel M., additional, George, Saby, additional, Carret, Anne-Sophie, additional, Yu, Yao, additional, Guseva, Maria, additional, Homet Moreno, Blanca, additional, and Flaig, Thomas W., additional

Published
2023
Full Text
View/download PDF

19. Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.

Author

Milowsky, Matthew I., primary, O'Donnell, Peter H., additional, Hoimes, Christopher J., additional, Petrylak, Daniel P., additional, Flaig, Thomas W., additional, Moon, Helen H, additional, Friedlander, Terence W., additional, Mar, Nataliya, additional, McKay, Rana R., additional, Srinivas, Sandy, additional, Gravis, Gwenaelle, additional, Ramamurthy, Chethan, additional, Bupathi, Manojkumar, additional, Bracarda, Sergio, additional, Wright, Phoebe, additional, Carret, Anne-Sophie, additional, Yu, Yao, additional, Matsuda, Tara, additional, Kataria, Ritesh S., additional, and Rosenberg, Jonathan E., additional

Published
2023
Full Text
View/download PDF

21. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis

Author

Torchia, Jonathon, Picard, Daniel, Lafay-Cousin, Lucie, Hawkins, Cynthia E, Kim, Seung-Ki, Letourneau, Louis, Ra, Young-Shin, Ho, King Ching, Chan, Tiffany Sin Yu, Sin-Chan, Patrick, Dunham, Christopher P, Yip, Stephen, Ng, Ho-keung, Lu, Jian-Qiang, Albrecht, Steffen, Pimentel, José, Chan, Jennifer A, Somers, Gino R, Zielenska, Maria, Faria, Claudia C, Roque, Lucia, Baskin, Berivan, Birks, Diane, Foreman, Nick, Strother, Douglas, Klekner, Almos, Garami, Miklos, Hauser, Peter, Hortobágyi, Tibor, Bognár, Laszló, Wilson, Beverly, Hukin, Juliette, Carret, Anne-Sophie, Van Meter, Timothy E, Nakamura, Hideo, Toledano, Helen, Fried, Iris, Fults, Daniel, Wataya, Takafumi, Fryer, Chris, Eisenstat, David D, Scheineman, Katrin, Johnston, Donna, Michaud, Jean, Zelcer, Shayna, Hammond, Robert, Ramsay, David A, Fleming, Adam J, Lulla, Rishi R, Fangusaro, Jason R, Sirachainan, Nongnuch, Larbcharoensub, Noppadol, Hongeng, Suradej, Barakzai, Muhammad Abrar, Montpetit, Alexandre, Stephens, Derek, Grundy, Richard G, Schüller, Ulrich, Nicolaides, Theodore, Tihan, Tarik, Phillips, Joanna, Taylor, Michael D, Rutka, James T, Dirks, Peter, Bader, Gary D, Warmuth-Metz, Monika, Rutkowski, Stefan, Pietsch, Torsten, Judkins, Alexander R, Jabado, Nada, Bouffet, Eric, and Huang, Annie

Published
2015
Full Text
View/download PDF

22. Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature

Author

Fossey, Mary, Li, Haocheng, Afzal, Samina, Carret, Anne-Sophie, Eisenstat, David D., Fleming, Adam, Hukin, Juliette, Hawkins, Cynthia, Jabado, Nada, Johnston, Donna, Brown, Tania, Larouche, Valerie, Scheinemann, Katrin, Strother, Douglas, Wilson, Beverly, Zelcer, Shayna, Huang, Annie, Bouffet, Eric, and Lafay-Cousin, Lucie

Published
2017
Full Text
View/download PDF

28. The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience

Author

Ailon, Tamir, Dunham, Christopher, Carret, Anne-Sophie, Tabori, Uri, Mcneely, P. Daniel, Zelcer, Shayna, Wilson, Beverley, Lafay-Cousin, Lucie, Johnston, Donna, Eisenstat, David D., Silva, Marianna, Jabado, Nada, Goddard, Karen Jane, Fryer, Chris, Hendson, Glenda, Hawkins, Cynthia, Dunn, Sandra, Yip, Stephen, Singhal, Ashutosh, and Hukin, Juliette

Published
2015
Full Text
View/download PDF

29. Incidence of medulloblastoma in Canadian children

Author

Johnston, Donna L., Keene, Daniel, Kostova, Maria, Strother, Douglas, Lafay-Cousin, Lucie, Fryer, Chris, Scheinemann, Katrin, Carret, Anne-Sophie, Fleming, Adam, Percy, Vanessa, Afzal, Samina, Wilson, Beverly, Bowes, Lynette, Zelcer, Shayna, Mpofu, Chris, Silva, Mariana, Larouche, Valerie, Brossard, Josee, and Bouffet, Eric

Published
2014
Full Text
View/download PDF

32. Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective Study

Author

Chellapandian, Deepak, Shaikh, Furqan, van den Bos, Cor, Somers, Gino R., Astigarraga, Itziar, Jubran, Rima, Degar, Barbara, Carret, Anne-Sophie, Mandel, Karen, Belletrutti, Mark, Dix, David, Visser, Johannes, Abuhadra, Nour, Chang, Tiffany, Rollins, Barret, Whitlock, James, Weitzman, Sheila, and Abla, Oussama

Published
2015
Full Text
View/download PDF

34. EZH2 Expression Is a Prognostic Factor in Childhood Intracranial Ependymoma: A Canadian Pediatric Brain Tumor Consortium Study

Author

Li, Amanda M., Dunham, Christopher, Tabori, Uri, Carret, Anne-Sophie, McNeely, Daniel P., Johnston, Donna, Lafay-Cousin, Lucie, Wilson, Beverly, Eisenstat, David D., Jabado, Nada, Zelcer, Shayna, Silva, Mariana, Scheinemann, Katrin, Fryer, Christopher, Hendson, Glenda, Fotovati, Abbas, Hawkins, Cynthia, Yip, Stephen, Dunn, Sandra E., and Hukin, Juliette

Published
2015
Full Text
View/download PDF

42. Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).

Author

Friedlander, Terence W., primary, Milowsky, Matthew I., additional, Bilen, Mehmet Asim, additional, Srinivas, Sandy, additional, McKay, Rana R., additional, Flaig, Thomas W., additional, Hoimes, Christopher J., additional, Balar, Arjun Vasant, additional, Henry, Elizabeth, additional, Petrylak, Daniel P., additional, Sasse, Carolyn, additional, Kataria, Ritesh S., additional, Yu, Yao, additional, Carret, Anne-Sophie, additional, and Rosenberg, Jonathan E., additional

Published
2021
Full Text
View/download PDF

49. Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.

Author

Mar, Nataliya, primary, Friedlander, Terence W., additional, Hoimes, Christopher J., additional, Flaig, Thomas W., additional, Bilen, Mehmet Asim, additional, Balar, Arjun Vasant, additional, Henry, Elizabeth, additional, Srinivas, Sandy, additional, Rosenberg, Jonathan E., additional, Petrylak, Daniel Peter, additional, Burgess, Earle Frederick, additional, Merchan, Jaime R., additional, Tagawa, Scott T., additional, Carret, Anne-Sophie, additional, Steinberg, Joyce Leta, additional, Chaney, Marya F., additional, and Milowsky, Matthew I., additional

Published
2020
Full Text
View/download PDF

50. Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

Author

Rosenberg, Jonathan E., primary, Flaig, Thomas W., additional, Friedlander, Terence W., additional, Milowsky, Matthew I., additional, Srinivas, Sandy, additional, Petrylak, Daniel Peter, additional, Merchan, Jaime R., additional, Bilen, Mehmet Asim, additional, Carret, Anne-Sophie, additional, Yuan, Nancy, additional, Sasse, Carolyn, additional, and Hoimes, Christopher J., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results